{
    "nct_id": "NCT04022213",
    "official_title": "Phase II Combination of 131I-Omburtamab Radioimmunotherapy and External Beam Radiotherapy for Desmoplastic Small Round Cell Tumor",
    "inclusion_criteria": "* Have the diagnosis of DSRCT confirmed at MSKCC\n* Age >1 year and able to cooperate with radiation safety restrictions during therapy period.\n* Prior to intraperitoneal catheter placement\n\n  * At least 1 weeks must have elapsed since prior chemotherapy\n  * At least 2 weeks must have elapsed since biologic therapy\n  * Toxicities of prior therapy must have resolved to grade 1 or less or to the patient's baseline\n\nAt the completion of surgery, patients must fulfill all of the additional following criteria:\n\n* Have no definitive radiological evidence of disease active in liver or outside the abdomen/pelvic OR have had GTR of this disease at the time of catheter placement\nHealthy volunteers allowed\nMust have minimum age of 1 Year",
    "exclusion_criteria": "* Prior progression of disease\n* Prior hypothermic intraperitoneal chemotherapy (HIPEC)\n* Cardiac, pulmonary, and neurologic toxicities are greater grade 1 per NCI CTCAE version 5\n* Renal, gastrointestinal, and hepatic, toxicities are greater than grade 2 (per NCI CTCAE version 5)\n* History of allergy to mouse proteins\n* Patients with grade 4 hypersensitivity reaction to radiolabeled iodine",
    "miscellaneous_criteria": ""
}